Oramed Pharmaceuticals (ORMP) Retained Earnings (2011 - 2026)
Oramed Pharmaceuticals (ORMP) posted Retained Earnings of -$85.1 million for Q1 2026, up 31.04% on a QoQ basis from -$123.4 million in Q4 2025, and up 53.8% year-over-year from -$55.3 million in Q1 2025.
Oramed Pharmaceuticals (ORMP) Retained Earnings (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals' Retained Earnings history runs 16 years deep, the most recent figure standing at -$85.1 million for Q1 2026.
- Quarterly Retained Earnings rose 53.8% year-over-year to -$85.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.1 million (up 53.8% YoY) and the FY2025 annual result came in at -$123.4 million, up 30.11% from the prior year.
- Retained Earnings was -$85.1 million for Q1 2026 at Oramed Pharmaceuticals, up from -$123.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $317.0 million in Q1 2023 and bottomed at -$184.3 million in Q1 2025.
- A 5-year average of -$45.1 million and a median of -$156.0 million in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings slumped 155.76% — and 2026, when it jumped 53.8%.
- Oramed Pharmaceuticals' Retained Earnings stood at -$163.1 million in 2022, then grew by 3.39% to -$157.6 million in 2023, then retreated by 12.1% to -$176.6 million in 2024, then surged by 30.11% to -$123.4 million in 2025, then surged by 31.04% to -$85.1 million in 2026.
- Business Quant data shows ORMP's Retained Earnings at -$85.1 million in Q1 2026, -$123.4 million in Q4 2025, and -$122.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Oramed Pharmaceuticals | 170.25 Mn | 170.25 Mn | - | -85.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.12 Mn |
| Dec 31, 2025 | -123.44 Mn |
| Sep 30, 2025 | -122.58 Mn |
| Jun 30, 2025 | -170.97 Mn |
| Mar 31, 2025 | -184.26 Mn |
| Dec 31, 2024 | -176.62 Mn |
| Sep 30, 2024 | -166.43 Mn |
| Jun 30, 2024 | -146.81 Mn |
| Mar 31, 2024 | -156.02 Mn |
| Dec 31, 2023 | -157.56 Mn |
| Sep 30, 2023 | -170.89 Mn |
| Jun 30, 2023 | -167.67 Mn |
| Mar 31, 2023 | 316.97 Mn |
| Dec 31, 2022 | -163.08 Mn |
| Sep 30, 2022 | 307.88 Mn |
| Jun 30, 2022 | 300.71 Mn |
| Mar 31, 2022 | 298.83 Mn |
| Nov 30, 2021 | 292.44 Mn |
| Aug 31, 2021 | 230.20 Mn |
| May 31, 2021 | -108.00 Mn |